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DISCUSSION: In general, patients preferred home treat-
ment to clinic treatment, and felt strongly that oral che-
motherapy was more convenient and not less effective.
This study suggests that many patients with recurrent
ovarian cancer value their time away from a clinical set-
ting and prefer oral chemotherapy at home. The reason
why patients prefer oral therapy is convenience and effec-
tiveness.
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OBJECTIVES: To estimate the effect of major micro-
and macrovascular complications on resource use and
cost in diabetic type 2 patients in Germany. METHODS:
Estimates for complication subgroups were based on re-
sults from the CODE-2 cost of illness study. The German
arm of the study analyzed data on resource utilisation of
809 patients with diabetes type 2 for 1998. A stratified
random sampling technique also allowed analysis for
rare subgroups. Direct and indirect cost were analysed
from a sickness fund perspective. RESULTS: The analysis
indicates that overall cost rises dramatically with devel-
opment of complications. The major cost driver was hos-
pitalization (see table below). CONCLUSIONS: The
study demonstrates the substantial cost burden; this sug-
Patient Reported Preferences and Beliefs, 1  strongly 
agree
Questions Oral (n  22)
IV 
(n  11)
IV more effective 3.1 3.3
Pills more effective 3.4 4.0
IV at clinic convenient 2.6* 1.0*
Pills convenient 0.4 1.2
Prefer pills at home 2.1* 3.6*
Worry about IV line started 3.2* 4.6*
Worry over emesis with pills 3.4 3.8
Questions
No Preference 
(n  6) P-value
IV more effective 3.5
Pills more effective 3.3
IV at clinic convenient 2.2 P  0.003
Pills convenient 1.5 P  0.025
Prefer pills at home 2.5 P  0.002
Worry about IV line started 2.8
Worry over emesis with pills 2.3
gests cost savings by preventing micro- and macrovascu-
lar complications.
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Complications of Type 1 diabetes mellitus (DM) increase
costs to the healthcare provider. Age is correlated with
complications as well as costs. OBJECTIVE: To estimate
diabetes-related costs due to complications separately
from age. METHODS: Members with Type 1 DM were
selected by ETG group from PharMetric’s Integrated
Outcomes database during 1997. Charges to the mem-
ber’s MCO for ED, pharmacy, in- and out-patient services
were tallied over CY 1997. Members were classified: (1)
as having 0,1, or 1 complications (nephropathy, retin-
opathy, neuropathy, or CAD), and (2) by age: 18, 18–44,
45–64, or 65. A regression of age and gender on
ln(charges) was compared to a regression of age, gender,
and complications. RESULTS: Over 41,000 members
were included in the study, about half male and female.
About 2/3 were 45 or older. Approximately 21,000
(52%) had 0 comorbidities, 12,000 (29%) had 1, and
7800 (19%) had 1; 92% of those 18 had 0 comor-
bidities; 65% of those 18–44 did; 47% of those 45–64
did; 34% of those 65 did. Similarly, 0.3% of those
18 had 1 comorbidity; 10% of those 18–44s, 21% of
No 
complications
Only 
macrovascular 
complications
Time since diagnosis 
of diabetes 6.5 8.4
Percentage of patients 
hospitalized 14% 26%
Number of days in hospital 
per patient and year 2.0 6.5
Hospitalization costs per 
patient and year [DM] 1,007 3,832
Total costs per patient 
and year [DM] 3,370 6,723
Only 
microvascular 
complications
Macro  
microvascular 
complications
Time since diagnosis of 
diabetes 10.6 12.6
Percentage of patients 
hospitalized 24% 41%
Number of days in hospital 
per patient and year 6.7 11.3
Hospitalization costs per 
patient and year [DM] 3,150 6,867
Total costs per patient 
and year [DM] 6,563 11,034
